After spending years unsuccessfully attempting to develop a Covid-19 vaccine, Inovio is now reporting promising results from ...

Inovio (INO) announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19. In the trial, ...

INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal ...

DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepointNo anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood ...